NEI Research News

LambdaVision, the Farmington, Connecticut-based biotech firm that developed the artificial retina, is exploring optimizing production of an artificial retina in space, in a series of missions to the International Space Station.

Researchers at Keck School of Medicine of USC develop signals that could bring color vision and improved clarity to prosthesis for the blind.

Scientists at the University of Pennsylvania School of Veterinary Medicine report findings of a gene therapy to treat a severe form of Leber congenital amaurosis, caused by mutations in the NPHP5 gene.

NEI-funded research at the University of Rochester has led to the development of a 3D lab model that mimics the part of the human retina affected in age-related macular degeneration.

The National Eye Institute (NEI) Data Commons now enables researchers to access data from patients with macular degeneration who participated in the Age-related Eye Disease Study 2 (AREDS2).

A broadly applicable AAV genome-coupled immunomodulation strategy helps cloak the AAV virus from unwanted immune responses, and offers important insights into ocular inflammation.

Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood.

Researchers at Georgia Tech have developed a potential new treatment for the eye disease glaucoma that could replace daily eyedrops and surgery with a twice-a-year injection to control the buildup of pressure in the eye.

The National Eye Institute (NEI) Audacious Goals Initiative (AGI) is exploring the possibility that the natural world holds the keys to restorative therapies that might unlock regenerative powers in humans.

A College of Veterinary Medicine & Biomedical Sciences and College of Pharmacy team believes the medication may also translate to the treatment of cataracts and uveitis in humans.